EZR

Across TCGA pan-cancer cohorts, EZR mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of EZR’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where EZR mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types EZR is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

PDAC, LSCC, and OV are the cancer types where EZR tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EZR mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	II,III,IV	+0.754	<.001	9	view →
LSCC	Male	II,III,IV	−0.347	<.001	8	view →
OV	All	All	+0.674	.002	2	view →
LUAD	Female	III,IV	−0.310	.008	2	view →
CCRCC	Male	All	−0.148	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

EZR–PDAC

Open the PDAC breakdown →